INFLIXIMAB RHEUMATOLOGY LOAD DOSE (SCHEDULE WEEKS 0, 2, 6)

Similar documents
PHYSICIAN ORDER SET : Patient: DOB: Gender: Patient Phone #: Height: Weight:

RITUXIMAB RHEUMATOLOGY VASCULITIS

2. Is the patient responding to Remicade therapy? Y N

Circle Yes or No Y N. [If no, skip to question 7.] 2. Does the patient have a diagnosis of ulcerative colitis? Y N. [If no, skip to question 4.

2. Does the patient have a diagnosis of ulcerative colitis or Crohn s? Y N

Zzbeacon,Zayna [MR ]

Prior Authorization Conditions for Approval of Enbrel (etanercept) Website Form Submit request via: Fax

3. Did the patient show evidence of remission by week 8 of Humira Y N therapy?

Request for Special Authorization Enbrel

IR Central Venous Access [ ] Pre Procedure

3. Does the patient have a diagnosis of rheumatoid arthritis (RA) with moderate to high disease activity?

PHYSICIAN ORDERS Diagnosis

Subject: Remicade (Page 1 of 5)

2. Does the patient have a diagnosis of Crohn s disease? Y N

3. Has the patient shown improvement in signs and symptoms of the disease? Y N

Pharmacy Prior Authorization

Appendix 1: Frequently Asked Questions

Inflectra Frequently Asked Questions

Ontario Public Drug Programs. Inflectra (infliximab) Frequently Asked Questions

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

Sample. Affix patient label within this box.

ADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

2. Has the patient had a response to treatment? Y N. 3. Does the patient have a diagnosis of rheumatoid arthritis (RA)? Y N

Pharmacy Prior Authorization

Pharmacy Prior Authorization

First Name. Specialty: Fax. First Name DOB: Duration:

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC

1. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA)?

(30689) PROT Pain PCA Adult Patient Controlled Analgesia

SAMPLE IgE: ESR: CRP: # Joints: %BSA: Height: Weight: BMI:

Title: Management of Allergic Reactions after IV Contrast in Magnetic Resonance Imaging

Neurosurgery Pre-Op [1710] Patient Name MRN. General. Nursing. Case Request [ ] Case request operating room Scheduling/ADT, Scheduling/ADT [ ] Other

Priority Health Medicare prior authorization form Fax completed form to: toll free, or

ETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

2019 Home Hemodialysis Standing Orders

PEDIATRIC SPINE SURGERY POST-OP PLAN - Phase:.

PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG

Prior Authorization Conditions for Approval of Humira (adalimumab) Website Form Submit request via: Fax

REMICADE Infliximab Consumer Medicine Information

PICU ADMIT DKA PLAN - Phase: Begin Immediately

CIMZIA (certolizumab pegol)

C. Assess clinical response after the first three months of treatment.

1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.

Zzbeacon,Zayna [MR ]

TRANSPARENCY COMMITTEE OPINION. 26 April 2006

Standardized Nurse Activated Protocols (SNAPs)

Humira (adalimumab) DRUG.00002

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

Immune Modulating Drugs Prior Authorization Request Form

INPATIENT INTERVENTIONAL RADIOLOGY PLAN - Phase: Pre-Procedure Orders

Diagnosis: Allergies with reaction type:

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

Drew University Health Service 36 Madison Avenue Madison, New Jersey Tel: Fax:

Physician Orders ADULT: Sickle Cell Inpatient Plan

PEDIATRIC SPINE SURGERY POST-OP PLAN - Phase: Pediatric Spine Surgery General Orders

Allergic reactions anaphylaxis *** CME Version *** Aaron J. Katz, AEMT-P, CIC

Drugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending

OBSERVATION UNIT ASTHMA PATHWAY OUTLINE Westmoreland Hospital PAGE 1 OF 5

Emergency Department Guideline. Anaphylaxis

Cardiac Catheter Labs Intravenous Drug Therapy Guide

PM-03 PED ALLERGY/ANAPHYLAXIS. Protocol SECTION: PM-03 PROTOCOL TITLE: PED ALLERGY/ANAPHYLAXIS REVISED: 01MAY2018

Home Care Services HomeMed MedEQUIP Michigan Visiting Care Michigan Visiting Nurses Wheelchair Seating Service PROCEDURE

Rituximab (Rituxan )

Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65

** Note: second generation antihistamines cause less drowsiness; may be beneficial in patients that need to drive themselves home.

Pharmacy Management Drug Policy

Anti-Tumor Necrosis Factor (Anti-TNF)

Amjevita (adalimumab-atto)

Transfusion Reactions

Mellen Center Approach to Ocrelizumab (Ocrevus)

Otezla. Otezla (apremilast) Description

USTEKINUMAB Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA GUIDELINES FOR USE

Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda)

Consent Laboratory Transfuse RBC

PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG

WHS POSTOPERATIVE POWERPLAN CHANGES

Remicade (infliximab) DRUG.00002

WEIGHT: KG HEIGHT: CM ALLERGY CAUTION sheet reviewed Code Status Full code

Stelara. Stelara (ustekinumab) Description

BENEFIT CHANGES TO NBPDP

Pharmacy Management Drug Policy

West Penn Allegheny Health System Forbes Regional Hospital

Cosentyx. Cosentyx (secukinumab) Description

To help you with terms and abbreviations used in this document that may be unfamiliar to you, a glossary is provided on the last pages.

Hip Hemiarthroplasty Post Op Version 2 4/20/17

Initials * Page 1 of 6. (place patient label here) Patient Name: Diagnosis: Allergies with reaction type:

Cimzia. Cimzia (certolizumab pegol) Description

Inflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG CG-DRUG-64

Bariatric Surgery Post Op Day Version 2 Approved 11/13/2017

Clinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012

Calumet 2017 staff/trainee/volunteer Health History & Examination Form PO Box 236, West Ossipee, NH Fax

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Infliximab/Infliximab-dyyb DRUG.00002

Authorization and appeals kit: Psoriatic arthritis

Physician s Order Form. Physician s Order Form. Telemetry/Progressive Care Orders. Continued on next page. >>>>>>> Continued on next page.

Clinical Policy: Secukinumab (Cosentyx) Reference Number: ERX.SPA.165 Effective Date:

UNC INFLAMMATORY BOWEL DISEASE DRUG PROTOCOL VEDOLIZUMAB (ENTYVIO)

Transcription:

. INFLIXIMAB RHEUMATOLOGY LOAD DOSE (SCHEDULE CDH 208-211 Approved 2/18 - Page 1 of 5 Patient: DOB: Gender: Patient Phone #: Height: Weight: Diagnosis: ICD-10 Code: Treatment Start Date: Provider Facility Name: Ordering Provider: Provider Facility Address: Date: Signature: Complete, Sign, and fax this document to: CDH Central Scheduling at 413-582-2183 **Please include H&P/current medications list/allergies, and ensure that med authorizations have been obtained**

CDH 208-211 Approved 2/18 - Page 2 of 5 Payor Requirements Provider Communication Once Until discont'd Select Diagnosis/Indication for use of Infliximab, or choose other: Rheumatoid Arthritis: 1. Is the patient currently taking methotrextate or does the patient have a contraindication to methotrexate? 3. Is the patient currently taking one other DMARD agent such as azathioprine, gold therapy, hydroxychloroquine, penicillamine, sulfasalazine, cyclosporine, or leflunomide? Psoriatic Arthritis: 1. Has the patient tried and failed treatment or have a contraindication to methotrexate? 3. Is the patient currently taking one other DMARD agent such as azathioprine, gold therapy, hydroxychloroquine, penicillamine, sulfasalazine, cyclosporine, or leflunomide? Ankylosing Spondylitis: 1. Has the patient tried and failed treatment with at least 1 NSAID? 3. Has patient had appropriate TB screening within Plaque Psoriasis: 1. Has the patient tried and failed or have contraindication to treatment with at least 2 of the following therapies: PUVA or UVB phototherapy, acitretin, cyclosporine, or methotrexate? 3. Has patient had appropriate TB screening within 4. Has patient had appropriate TB screening within 4. Has patient had appropriate TB screening within Other: Please document here the diagnosis/indication for this patient to receive Infliximab therapy, as well as any supporting documentation for its medical necessity: If No to one or more questions above, please add documentation to support medical necessity:

CDH 208-211 Approved 2/18 - Page 3 of 5 Pre-Medications acetaminophen (TYLENOL) tablet 650 mg Every 2 weeks 3 treatments 650 mg, Oral, Once, Starting S, For 1 Doses diphenhydramine (BENADRYL) oral 25 mg Every 2 weeks 3 treatments 25 mg, Oral, Once, Starting at treatment start time, For 1 dose HOLD IF: Given IV. diphenhydramine (BENADRYL) IV 25 mg Every 2 weeks 3 treatments 25 mg, Intravenous, Once as needed, If unable to take PO, when released, For 1 dose HOLD IF: Given PO. loratadine (CLARITIN) tablet 10 mg Every 2 weeks 3 treatments 10 mg, Oral, Once, Starting S, For 1 Doses methylprednisolone sodium succinate (SOLU-Medrol) IV 40 mg Every 2 weeks 3 treatments 40 mg, Intravenous, Once, Starting S, For 1 Doses Medications Interval Defer Until Duration infliximab (REMICADE) infusion 3 mg/kg Every 2 weeks 3 treatments 3 mg/kg, Intravenous, Once, Starting 30 minutes after treatment start time, For 1 Dose Follow your institutional guidelines for titration and duration of infusion. Use an in-line, sterile, non-pyrogenic, low protein-binding filter of 1.2 micron or LESS. Catheter management Line Access PRN Until discont'd Routine, Once, Starting S For 1 Occurrences, As needed. Starting when released. Until Specified. Insert peripheral IV, or access peripheral, or central venous access device, to provide treatment. alteplase (CATHFLO) 1 mg/ml injection 2 mg PRN Until discont'd 2 mg, Intracatheter, As needed, line care, For central venous access device requiring clearance. Administer per institutional guidelines. May repeat once per lumen., Starting S lidocaine-prilocaine (EMLA) cream PRN Until discont'd Topical, As needed, pre procedure/treatment, Apply prior to the PIV insertion or port access, Starting S heparin 100 units/ml flush 5 ml PRN Until discont'd 5 ml, Intravenous, As needed, line care, Line care per institutional guidelines, Starting S heparin 10 units/ml flush 3 ml PRN Until discont'd 3 ml, Intravenous, As needed, line care, Line care per institutional guidelines, Starting S heparin 10 units/ml flush 5 ml PRN Until discont'd 5 ml, Intravenous, As needed, line care, Line care per institutional guidelines, Starting S heparin 1000 units/ml flush 2 ml PRN Until discont'd 2 ml, Intracatheter, As needed, line care, APHERESIS LINE CARE ONLY per institutional policy. HEPARIN MUST BE WITHDRAWN FROM EACH LUMEN PRIOR TO FLUSHING OR INFUSING THROUGH THE APHERESIS CATHETER, Starting S sodium chloride (NS) 0.9 % syringe flush 3 ml PRN Until discont'd 3 ml, Intravenous, As needed, line care, Line care per institutional guidelines, Starting S

CDH 208-211 Approved 2/18 - Page 4 of 5 Catheter management (continued) sodium chloride (NS) 0.9 % syringe flush 10 ml PRN Until discont'd 10 ml, Intravenous, As needed, line care, Line care per institutional guidelines, Starting S sodium chloride (NS) 0.9 % syringe flush 20 ml PRN Until discont'd 20 ml, Intravenous, As needed, line care, Line care per institutional guidelines, Starting S sodium chloride 0.9% infusion PRN Until discont'd 20 ml/hr, Intravenous, Continuous PRN, other (free text field), Keep vein open to provide treatment, Starting S D5W infusion PRN Until discont'd 20 ml/hr, Intravenous, Continuous PRN, other (free text field), Keep vein open to provide treatment, Starting S Emergency Medications/Anaphylaxis Provider and Nurse Communication PRN Until discont'd Routine, Until discontinued, Starting S, Treatment of SEVERE reaction (ANAPHYLAXIS): hypotension, throat swelling, wheezing, respiratory distress, or decreased oxygen saturation. Stop the infusion and treat with epinephrine FIRST. Notify provider and emergency personnel, administer oxygen as needed, monitor vital signs and proceed with administering adjunct HYPERSENSITIVITY medications as clinically indicated. EPINEPHrine injection 0.3 mg PRN Until discont'd 0.3 mg, Intramuscular, As needed, anaphylaxis, Administer FIRST for anaphylaxis. May repeat times 1 dose, Starting S For 2 doses. Pharmacy's Suggested Dose Instructions; Epinephrine 1:1000 is equivalent to 1 mg/ml sodium chloride 0.9% bolus 1,000 ml PRN Until discont'd 1,000 ml, Intravenous, Once as needed, other (free text field), For hypotension, Starting S, For 1 Doses Oxygen Therapy - Non-Rebreather PRN Until discont'd Routine Select a Mode of Therapy: Non-Rebreather

CDH 208-211 Approved 2/18 - Page 5 of 5 Hypersensitivity Provider and Nurse Communication PRN Until discont'd Routine, Until discontinued, Starting S For Until specified, Treatment for mild-moderate infusion reaction: Stop the infusion, notify provider and emergency personnel, administer oxygen as needed, monitor vital signs and proceed with administering medications as clinically indicated. If ANAPHYLAXIS reaction, refer to Emergency Medications section. albuterol (ACCUNEB) nebulizer solution 2.5 mg PRN Until discont'd 2.5 mg, Nebulization, Once as needed, shortness of breath, wheezing, wheezing, shortness of breath, Starting S, For 1 Doses acetaminophen (TYLENOL) tablet 975 mg PRN Until discont'd 975 mg, Oral, Once as needed, fever, Starting S, For 1 Doses diphenhydramine (BENADRYL) injection 25 mg PRN Until discont'd 25 mg, Intravenous, As needed, itching, itching, hives. Begin with 25 mg. If patient has continued reaction, administer additional 25 mg, Starting S famotidine (PEPCID) injection 20 mg PRN Until discont'd 20 mg, Intravenous, Once as needed, other (free text field), Adjunct treatment for mild-moderate, or SEVERE reaction Hold if: given as premed, Starting S, For 1 Doses cetirizine (ZyrTEC) tablet 10 mg PRN Until discont'd 10 mg, Oral, Once as needed, allergies, Adjunct treatment for mild-moderate, or SEVERE reaction, Starting S, For 1 Doses HOLD IF giving fexofenadine. fexofenadine (ALLEGRA) tablet 180 mg PRN Until discont'd 180 mg, Oral, Once as needed, allergies, Adjunct treatment for mild-moderate, or SEVERE reaction, Starting S, For 1 Doses HOLD IF giving cetirizine. methylprednisolone sodium succinate (SOLU-Medrol) IV 40 mg PRN Until discont'd 40 mg, Intravenous, Once as needed, other (free text field), Adjunct treatment for mild-moderate, or SEVERE reaction, Starting S, For 1 Doses ondansetron (ZOFRAN) injection 4 mg PRN Until discont'd 4 mg, Intravenous, As needed, nausea, vomiting, may repeat x 1 dose, Starting S, For 2 Doses meperidine (DEMEROL) injection 25 mg PRN Until discont'd 25 mg, Intravenous, Once as needed, rigors, Starting when released